Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xellar Biosystems

Explore full profile

Accelerating drug discovery through human-mimetic organ-on-a-chip technology, high-fidelity 3D disease models, and AI-powered spatiotemporal profiling.

Boston, United StatesFounded 2022Biotech & Life Sciences
Valuation $100–250M Last recorded · 2026
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Xellar Biosystems and the history behind them.

About Xellar Biosystems

Xellar Biosystems, formerly called Beijing Power Yaosu Technology, is a biotechnology startup that operates in the pharmaceutical industry, specifically in the area of drug discovery. The company leverages a unique blend of Wet Artificial Intelligence (AI), machine learning, and large-scale wet-lab experiments to address the complex challenges of modern drug discovery. Wet AI is a term used to describe the integration of AI and machine learning with biological experiments.

Read full description

The company's innovative approach aims to harness the complexity of human biology to expedite the process of drug discovery and development. Traditional methods in this field have relied on simplified models and reductionistic tools, which often fail to capture the intricate interconnections of the human body. Xellar Biosystems, however, uses a more holistic approach, recognizing that the human body is a complex, interconnected system.

Xellar Biosystems' business model is likely based on partnerships with pharmaceutical companies and research institutions. By offering its advanced drug discovery platform, the company can help these entities accelerate their drug development processes, potentially saving them significant time and resources. This, in turn, could lead to faster approval and commercialization of new drugs, providing a valuable service to the pharmaceutical industry.

In terms of revenue generation, Xellar Biosystems likely charges for access to its platform and services, possibly on a subscription or per-use basis. The company could also generate income through strategic partnerships, licensing agreements, or by offering additional services such as data analysis or consulting.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2022
Headquarters
Boston, United States
Employees
27
Open positions
1
Dealroom signal
88.1/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Drug Development
Technology
Artificial Intelligence, Hardware, Deep Tech, Machine Learning, Deep Learning, Nanotech, Computer Vision
Business model
Manufacturing
Client focus
b2b

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Jun 2026 $29M $118M Oriental Fortune Capital · Yael Capital Management · Cedarlake Capital · GF Securities ↗
SERIES AOther financing Apr 2026 $29M $116M Yayi Capital · China Life Private Equity Investment · Legend Capital · XtalPi ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Xellar Biosystems website traffic

Latest recorded traffic for Xellar Biosystems is 790 monthly website visits, down 76.1% over the last three months. Xellar Biosystems's team grew 22.7% over the past year.

Latest monthly visits790 3-month web change-76.1% 1-year team growth+22.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A12 investors entered at this stage

  • Legend Capital
  • TriApex Laboratories
  • Tiantu Capital
  • Yael Capital Management
  • Zhengxuan Investment
  • China Life Private Equity Investment
  • Yayi Capital
  • XtalPi
  • Oriental Fortune Capital
  • Cedarlake Capital
  • GF Securities
  • Qingsong Capital

Other known investors1 additional known investor

  • Northeastern University
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States73.7%
🇨🇳 China15.8%
🇨🇦 Canada5.3%
🇨🇴 Colombia5.3%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xellar Biosystems on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xellar Biosystems’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.